Immunohistochemical Expression of Extracellular Matrix Protein-1 in Neoplastic Thyroid Lesions

Authors

  • Nazoora Khan Department of Pathology, Jawaharlal Nehru medical college, AMU, Aligarh (UP), India
  • Hena Ayyub Ansari Department of Pathology, Jawaharlal Nehru medical college, AMU, Aligarh (UP), India
  • Naba Hasan Department of Pathology, Jawaharlal Nehru medical college, AMU, Aligarh (UP), India
  • Mohammad Amanullah Khan Department of Surgery, Jawaharlal Nehru medical college, AMU, Aligarh (UP), India

DOI:

https://doi.org/10.21276/apalm.2827

Keywords:

Extracellular matrix protein-1, Reverse transcriptase polymerase chain reaction, Neoplastic lesions of thyroid, Immunohistochemistry

Abstract

Background: Upregulated Extracellular matrix protein 1 (ECM 1) expression has been observed in several malignancies including breast, thyroid carcinoma, cutaneous melanoma and gastric carcinoma. ECM 1 expression has been evaluated in various epithelial malignancies using real time – reverse transcriptase polymerase chain reaction (RT-PCR). The purpose of current study is to evaluate the immunohistochemical expression of ECM 1 in various neoplastic lesions of thyroid.

 

Methods: The study included 81 neoplastic thyroid tissue specimens (21 benign and 60 malignant lesions) received over a period of 5 years (2012-2017). Hematoxylin and Eosin stained sections of the tissue specimens were carefully examined under light microscope in order to establish the histopathological diagnosis. The immunohistochemical marker ECM 1 was applied on appropriate sections and the slides were evaluated accordingly.

 

Result: The expression of ECM 1 was nil (grade 0, 47.62% cases) or weak (1+, 52.38% cases) in benign lesions while majority of malignant lesions (78.33%) showed strong homogenous and crisp staining (3+). The difference in the expression of ECM 1 between benign and malignant lesions was found to be statistically significant (p < 0.001). ECM 1 has a diagnostic accuracy of 0.82 and sensitivity of 100% in differentiating benign from malignant lesions.

 

Conclusion: ECM 1 is uniformly upregulated in all malignant thyroid neoplasms irrespective of the histological type of malignancy. Immunohistochemical expression of ECM 1 shows comparable results to RT-PCR. ECM 1 immunohistochemistry can thus serve as an important standalone marker of malignant thyroid tissue.

References

1. Maitra A. The endocrine system. In: Kumar V, Abbas AK, Aster JL, editors. Robbins & cotran pathologic basis of disease.9th ed. New Delhi: Reed Elsevier India Private Limited; 2014. 1082-1100.
2. Freitas BCG and Cerutti JM. Genetic markers differentiating follicular thyroid carcinoma from benign lesions. Molecular and Cellular Endocrinology. 2009; 321(1): 77-85.
3. Jung CK, Min HS, Park HJ, Song DE, Kim JH, Park SY et al. Pathology reporting of thyroid core needle biopsy: a proposal of the Korean Endocrine Pathology Thyroid Core Needle Biopsy Study Group. Journal of pathology and translational medicine. 2015; 49(4): 288-299.
4. Sercu S, Zhang M, Oyama N, Hansen U, Ghalbzouri AE, Jun G et al. Interaction of extracellular matrix protein 1 with extracellular matrix components: ECM1 is a basement membrane protein of the skin. Journal of Investigative Dermatology. 2008; 128(6):1397-1408.
5. Wang L, Yu J, Ni J, Xu XM, Wang J, Ning H et al. Extracellular matrix protein 1 (ECM1) is over-expressed in malignant epithelial tumors. Cancer letters. 2003; 200(1): 57-67.
6. Lal G, Hashimi S, Smith BJ, Lynch CF, Zhang L, Robinson RA et al. Extracellular matrix 1 (ECM1) expression is a novel prognostic marker for poor long-term survival in breast cancer: a Hospital-based Cohort Study in Iowa. Annals of surgical oncology. 2009; 16(8): 2280-2287.
7. Chen H, Jia WD, Li JS, Wang W, Xu GL, Ma JL et al. Extracellular matrix protein 1, a novel prognostic factor, is associated with metastatic potential of hepatocellular carcinoma. Medical Oncology. 2011; 28(1): 318-325.
8. Wu Q, Li X, Yang H, Lu C, You J, Zhang Z. Extracellular matrix protein 1 is correlated to carcinogenesis and lymphatic metastasis of human gastric cancer. World journal of surgical oncology. 2014; 12(1): 132-137.
9. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A. ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Annals of surgery. 2005; 242(3): 353-359.
10. Lal G, Padmanabha L, Nicholson R, Smith BJ, Zhang L, Howe JR et al. ECM1 expression in thyroid tumors—a comparison of real-time RT-PCR and IHC. Journal of Surgical Research. 2008; 149(1): 62-68.
11. Na DG, Kim JH, Sung JY, Baek JH, Jung KC, Lee H, et al. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology. Thyroid. 2012; 22:468-475.
12. Sung JY, Na DG, Kim KS, Yoo H, Lee H, Kim JH et al. Diagnostic accuracy of fine-needle aspiration versus core-needle biopsy for the diagnosis of thyroid malignancy in a clinical cohort. European radiology. 2012; 22(7):1564-1572.
13. Izkhakov E, Somjen D, Sharon O, Knoll E, Aizic A, Fliss DM, Limor R, Stern N. Vitamin D receptor expression is linked to potential markers of human thyroid papillary carcinoma. The Journal of steroid biochemistry and molecular biology. 2016; 159:26-30.
14. Zhang K, Liu J, Li C, Peng X, Li H, Li Z. Identification and validation of potential target genes in papillary thyroid cancer. European journal of pharmacology. 2019; 843:217-25.
15. Pauws E, Veenboer GJ, Smit JW, de Vijlder JJ, Morreau H, Ris-Stalpers C. Genes differentially expressed in thyroid carcinoma identified by comparison of SAGE expression profiles. The FASEB journal. 2004; 18(3):560-571.
16. Poma AM, Giannini R, Piaggi P, Ugolini C, Materazzi G, Miccoli P, Vitti P, Basolo F. A six-gene panel to label follicular adenoma, low-and high-risk follicular thyroid carcinoma. Endocrine connections. 2018; 7(1):124-32.
17. De Matos LL, Del Giglio AB, Matsubayashi CO, De Lima FM, Del Giglio A, Da Silva PMA. Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagnostic Pathology. 2012; 7:95-97.

Downloads

Published

25-09-2020

How to Cite

1.
Khan N, Ansari HA, Hasan N, Khan MA. Immunohistochemical Expression of Extracellular Matrix Protein-1 in Neoplastic Thyroid Lesions. Ann of Pathol and Lab Med [Internet]. 2020 Sep. 25 [cited 2024 Dec. 26];7(9):A439-444. Available from: https://pacificejournals.com/journal/index.php/apalm/article/view/2827

Issue

Vol. 7 No. 9 (2020)

Section

Original Article

License

Copyright (c) 2020 Nazoora Khan, Hena Ayyub Ansari, Naba Hasan, Mohammad Amanullah Khan

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).

 

Crossref
Scopus
Google Scholar
Europe PMC